SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Files Class Action Suit Against Dimension Therapeutics, Inc.

WILMINGTON, Del., Oct. 31, 2017 -- Rigrodsky & Long, P.A.:

Rigrodsky & Long, P.A. announces that it has filed a class action complaint in the United States District Court for the District of Massachusetts on behalf of holders of Dimension Therapeutics, Inc. (“Dimension”) (Nasdaq:DMTX) common stock in connection with the proposed acquisition of Dimension by Ultragenyx Pharmaceutical Inc. and its affiliate (“Ultragenyx”) announced on October 3, 2017 (the “Complaint”).  The Complaint, which alleges violations of the Securities Exchange Act of 1934 against Dimension, its Board of Directors (the “Board”), and Ultragenyx, is captioned Scarantino v. Dimension Therapeutics, Inc., Case No. 1:17-cv-11964 (D. Mass.).

If you wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact plaintiff’s counsel, Seth D. Rigrodsky or Gina M. Serra at Rigrodsky & Long, P.A., 2 Righter Parkway, Suite 120, Wilmington, DE 19803, by telephone at (888) 969-4242, by e-mail at [email protected], or at http://rigrodskylong.com/contact-us/. 

On October 2, 2017, Dimension entered into an agreement and plan of merger (the “Merger Agreement”) with Ultragenyx.  Pursuant to the Merger Agreement, shareholders of Dimension will receive $6.00 in cash for each share of Dimension common stock they own (the “Proposed Transaction”).

Among other things, the Complaint alleges that, in an attempt to secure shareholder support for the Proposed Transaction, defendants issued materially incomplete disclosures in a Solicitation Statement (the “Solicitation Statement”) filed with the United States Securities and Exchange Commission.  The Complaint alleges that the Solicitation Statement omits material information necessary to enable shareholders to make an informed decision as to how to tender their shares in the tender offer, including material information with respect to Dimension’s financial projections and potential conflicts of interest.  The Complaint seeks injunctive and equitable relief and damages on behalf of holders of Dimension common stock. 

If you wish to serve as lead plaintiff, you must move the Court no later than January 2, 2018.  A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.  Any member of the proposed class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.

Rigrodsky & Long, P.A., with offices in Wilmington, Delaware and Garden City, New York, regularly prosecutes securities fraud, shareholder corporate, and shareholder derivative litigation on behalf of shareholders in state and federal courts throughout the United States.

Attorney advertising.  Prior results do not guarantee a similar outcome.

CONTACT:                                                                                             

Rigrodsky & Long, P.A.
Seth D. Rigrodsky
Gina M. Serra
(888) 969-4242
(302) 295-5310
Fax: (302) 654-7530
[email protected]
http://www.rigrodskylong.com